ChromaDex External Research Program (CERP™) Celebrates 100 Peer-Reviewed Published Studies on Niagen® and Other Ingredients
January 31 2022 - 6:32AM
Business Wire
ChromaDex’s research & development program
reaches 100 published peer-reviewed studies on Niagen® and other
ingredients
ChromaDex Corp. (NASDAQ:CDXC) celebrates the ChromaDex External
Research Program’s (CERP™) 100th published peer-reviewed study on
the company’s flagship ingredient Niagen® (patented nicotinamide
riboside, or “NR”) and other proprietary ingredients. CERP, the
program pioneering NR research, is the first-of-its-kind to reach
such a milestone. The recently published preclinical trial in the
Investigative Ophthalmology & Visual Science Journal
investigated the effects of NR on male rats under treatment of
paclitaxel, a chemotherapy drug that can cause ocular discomfort
and dry eye-like symptoms. Of note, the investigators found that NR
supplementation reversed paclitaxel-induced discomfort in the
cornea of rats. This milestone preclinical study joins a growing
body of clinical and preclinical evidence supporting health
benefits of NR supplementation.
CERP was established to advance the science of nicotinamide
riboside and other ChromaDex products. To date, the program has
produced more than 45% of all peer-reviewed NR-focused
publications, and 70% of the peer-reviewed clinical NR
publications. This speaks to the tremendous value of the program.
Over 90% of studies in CERP are investigator-initiated and third
party funded. This approach results in greater trust in the
research, as skepticism of industry-funded research has been a
challenge in the dietary supplement industry.
“Our goal through CERP is to be the industry standard for
excellence in research. We are very excited about this milestone
and advancing clinical and preclinical research on Niagen® in
2022,” says Dr. Yasmeen Nkrumah-Elie, ChromaDex Global Director of
R&D for External Research. “We are looking forward to advancing
the science of NR through clinical translation. We hope that CERP
can serve as a torch for the industry, and other companies will
develop similar programs to promote the science of dietary
supplements.”
ChromaDex’s flagship Niagen® (patented nicotinamide riboside, or
“NR”) ingredient has been at the forefront of NAD+ research and
healthy aging categories. Niagen® replenishes levels of NAD+,
supports healthy cellular metabolism, and helps mitochondria
function more efficiently to promote healthy aging at the cellular
level. The research conducted by independent investigators through
CERP™ has expanded the understanding of NR in key health areas
including Ataxia-telangiectasia, skeletal muscle, liver health, and
heart failure. For example:
- Zeybel et al., 2021 found a reduction in liver fat and
inflammatory markers in patients with non-alcoholic fatty liver
disease (NAFLD) when receiving a nutritional protocol including
nicotinamide riboside (NR), L-serine, N-acetyl-L-cysteine (NAC),
and L-carnitine tartrate.
(https://www.embopress.org/doi/full/10.15252/msb.202110459)
- Zhou et al., 2020 demonstrated NR reduced the production of
inflammatory cytokines, as well as improved the mitochondrial
health of peripheral blood mononuclear cells (PBMCs) in Stage D
heart failure patients.
(https://www.jci.org/articles/view/138538)
- Zhang et al., 2020 illustrated a combination supplement
consisting of 1g NR, 20g L-serine, 5g N-acetyl-L-cysteine, and 3g
L-carnitine significantly decreased human blood plasma levels of
markers associated with increased liver fat, as well as blood
plasma levels of branched chain amino acids associated with insulin
resistance and development of type 2 diabetes, compared to
baseline. (https://pubmed.ncbi.nlm.nih.gov/32337855/)
“Since its inception, CERP has served as the model for
industry-academia collaborative research and intellectual property
generation,” says Dr. Andrew Shao, ChromaDex Senior Vice President
of Global Scientific & Regulatory Affairs. “Achieving this
milestone would not have been possible without all the CERP
investigators and their respective institutions. We are grateful
for their contributions and look forward to many more future
research opportunities.”
Started in 2013 by ChromaDex Co-Founder and Executive Chairman
Frank Jaksch, CERP™ has been advancing the science of NR and NAD+
among other materials. This unique, industry-leading program has
helped to produce the trusted science behind Niagen® by
accumulating more than 245 collaborative agreements (MTAs) with
over 170 institutions in 33 countries, representing over $85
million in estimated total research value. The program has also
resulted in a patent portfolio of over 40 granted patents relating
to Niagen® and other precursors to NAD+.
For additional information on the science supporting Niagen®
visit www.chromadex.com.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to results of the NIAGEN®
studies, their significance and whether the studies show potential
for benefits on human health. Statements that are not a description
of historical facts constitute forward-looking statements and may
often, but not always, be identified by the use of such words as
"expects," "anticipates," "intends," "estimates," "plans,"
"potential," "possible," "probable," "believes," "seeks," "may,"
"will," "should," "could" or the negative of such terms or other
similar expressions. More detailed information about ChromaDex and
the risk factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2020, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220131005229/en/
ChromaDex Media Contact: Alex Worsham, Vice President of
Global Marketing & Communications 310-388-6706 ext. 689
alexw@chromadex.com
ChromaDex Investor Relations Contact: Brianna Gerber,
Vice President of Finance and Investor Relations 949-419-0288 ext.
127 briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jun 2024 to Jul 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jul 2023 to Jul 2024